Becton, Dickinson and Company (BDX) has been the subject of a variety of news updates. Despite its stock weakness, BDX's decent financials suggest the market might correct its share price. The consensus recommends it as a strong 'Buy' on Wall Street and some consider it as one of the best income stocks. Significantly, BDX has increased its dividends for 53 consecutive years. However, their shares seem to be underperforming compared to the Dow. Noteworthy transactions include World Investment Advisors and State Street Corp increasing their shares, while Vestcor Inc and Saratoga Research & Investment Management have offloaded BDX stocks. The stock's weak financials aren't thought to represent its high-quality earnings. Looking ahead, BDX's Q4 earnings and revenues surpassed estimates. BDX is recognized as a top value stock for the long term and is a solid growth stock due to three key reasons – its potential to manage its debt responsibly, the acquisition of critical care from Edwards Lifesciences, and its convincing expansion in advanced monitoring technology. BDX is leveraging its innovations in medical technology and its robotics solution recently launched should boost single cell research. Nevertheless, bear in mind that investors betting on BDX five years ago are currently facing a 4.7% loss.
Becton Dickinson and BDX News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 14 Dec 2024 11:13:22 GMT -
Rating 5
- Innovation -3
- Information 8
- Rumor -7
